

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6361639

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
POTENTIA PHARMACEUTICALS, INC.	09/08/2015
RECEIVING PARTY DATA	
Name:	APELLIS PHARMACEUTICALS, INC.
Street Address:	6400 WESTWIND WAY, SUITE A
City:	CRESTWOOD
State/Country:	KENTUCKY
Postal Code:	40014
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	11544389
CORRESPONDENCE DATA	
Fax Number:	(617)502-5002
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6172485000
Email:	patentdocket@choate.com
Correspondent Name:	CHOATE HALL & STEWART LLP
Address Line 1:	TWO INTERNATIONAL PLACE
Address Line 4:	BOSTON, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	2008575-0182
NAME OF SUBMITTER:	SOWMYA SUBRAMANIAN
SIGNATURE:	/Sowmya Subramanian/
DATE SIGNED:	10/21/2020
Total Attachments: 6	
source=2008575-0182-Assignment#page1.tif	
source=2008575-0182-Assignment#page2.tif	
source=2008575-0182-Assignment#page3.tif	
source=2008575-0182-Assignment#page4.tif	
source=2008575-0182-Assignment#page5.tif	
source=2008575-0182-Assignment#page6.tif	

PATENT ASSIGNMENT

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Potentia Pharmaceuticals, Inc. ("Assignor"), hereby assigns to Apellis Pharmaceuticals, Inc., a Delaware corporation having a place of business at 6400 Westwind Way, Suite A, Crestwood, KY 40014 ("Buyer" and herein also referred to as "Assignee"), all of Assignor's right, title and interest in and to the below-identified patents, patent registrations and patent applications ("Patent Rights"), including all rights to sue for past infringement, the same to be held and enjoyed by Buyer, its successors and assigns, in and throughout the United States of America, its territories and all foreign countries, including but not limited to Assignor's right, title and interest in and to the invention(s) described in said Patent Rights and such letters patents as may issue from patent applications included within the Patent Rights, including but not limited to non-provisionals, continuations, divisionals, reissues, reexaminations, extensions, and substitutions of said application(s) or such patents, and all priority rights appertaining thereto; said Patent Rights to be held and enjoyed by said Assignee for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said letters patents may be granted as fully and entirely as the same would have been held by Assignor had this assignment and sale not been made. Assignor hereby conveys all of Assignor's rights arising under or pursuant to any and all United States laws and international agreements, treaties or laws relating to the protection of industrial property by the filing of any such application(s) within the Patent Rights, including but not limited to any cause(s) of action and damages accruing prior to this assignment. Assignor hereby acknowledges that this assignment, being of Assignor's entire right, title and interest in and to said invention(s), carries with it the right in Assignee to apply for and obtain from competent authorities in all countries of the world any and all letters patent by attorneys and agents of Assignee's selection and the right to procure the grant of all letters patent to Assignee in its own name as assignee of Assignee's entire right, title and interest therein;

AND, Assignor hereby further agrees for ourselves and our executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the aforesaid invention(s) to said Assignee, its successors, assigns, and legal representatives, including the execution of non-provisional, substitution, continuation, divisional, reissue, reexamination, or corresponding foreign or international patent applications but at Assignee's own expense and charge;

AND, Assignor hereby further agrees to provide factual statements or testimony in any interference or other proceeding in which said invention(s) or any application or patent directed thereto may be involved;

AND, Assignor hereby authorizes and requests the Director of the United States Patent and Trademark Office and such patent office officials in foreign countries as are duly authorized by their laws to issue patents to issue such letters patent as shall be granted upon applications included within the Patent Rights, or applications based thereon, to said Assignee, its successors, assigns, or legal representatives;

Executed as of the 8th day of September, 2015.

POTENTIA PHARMACEUTICALS, INC.

By: 

Name:

PASCAL VACHATELET

Title:

COO

[Signature Page to Patent Assignment]

We, Apellis Pharmaceuticals, Inc, attest that this document is a true copy of the original assignment dated 8 September 2015 and accept the assignment contained therein.

Date:

July 19, 2016

Signature:



Name:

PASCAL PESCHALEVED

Capacity:

COO

7675593v1

FAMILY: COMPFSTAIN AND ANALOGS THEREOF FOR EYE DISORDERS

TITLE	APPN TYPE	COUNTRY/ SER. NO.	FILING DATE*	PATENT NUMBER	STATUS
COMPFSTAIN AND ANALOGS THEREOF FOR EYE DISORDERS	PROV	US 60725,484	10/08/05		Expired
COMPFSTAIN AND ANALOGS THEREOF FOR EYE DISORDERS	PROV	US 60725,447	10/12/05		Expired
METHODS OF TREATING AGE-RELATED MACULAR DEGENERATION BY COMPFSTAIN AND ANALOGS THEREOF	PARENT	US 11/544,389	10/06/06	8,168,584	Issued
METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION COMPRISING ADMINISTERING A COMPFSTAIN ANALOG	CONTINUATION	US 13/409,941	3/1/12	9,056,076	Issued
COMPFSTAIN AND ANALOGS THEREOF FOR EYE DISORDERS	CONTINUATION	US 14/705,592	5/6/15		Pending
COMPFSTAIN AND ANALOGS THEREOF FOR EYE DISORDERS	PCT	PCT/US06/039297 Published as WO/2007/044668	10/06/06		Nationalized
"	PARENT	Australia 2006302212	10/06/06	2006302212	Issued
"	PARENT	Brazil PI0617186-9	10/06/06		Pending
"	PARENT	Canada 2,625,206	10/06/06		Pending
"	PARENT	China 200689046037.1	10/06/06		Pending
"	DIVISIONAL	China 201310385036.1	10/06/06		Pending
"	PARENT	Europe 06825651.0	10/06/06		Pending
"	PARENT	Hong Kong 09101086.4	10/06/06		Pending
"	PARENT	Israel 190695	10/06/06		Pending
"	PARENT	Japan 2008-534756	10/06/06	5345849	Issued
"	DIVISIONAL	Japan 2013-077986	10/06/06		Pending
"	PARENT	Mexico MX/a/2006/004656		299781	Issued

"	DIVISIONAL	Mexico MX/a/2012/006324	Pending	Pending
---	------------	----------------------------	---------	---------

FAMILY: INJECTABLE COMBINATION THERAPY FOR EYE DISORDERS

TITLE	APPN TYPE	COUNTRY/ SER. NO.	FILING DATE*	PATENT NUMBER	STATUS
INJECTABLE COMBINATION THERAPY FOR EYE DISORDERS	PROV	US 60760,974	1/19/06		Expired
"	PCT	PCT/US07/01649 Published as WO/2007084765	1/19/07		Nationalized
"	PARENT	US 12/161,410	1/19/07		Abandoned
"	CONTINUATION	US 14/744,019			Pending
"	PARENT	Europe Ser. No. 07718112.1	1/19/07		Pending
"	PARENT	Australia 2007207385	1/19/07	2007207385	Issued
"	DIVISIONAL	Australia Ser. No. 2013203946	1/19/07		Pending
"	PARENT	Japan 2008-551458	1/19/07		Pending
"	DIVISIONAL	Japan 2013-086862	1/19/07		Pending

FAMILY: SUSTAINED DELIVERY OF COMPOSTATIN ANALOGS FROM GELS

TITLE	APPN TYPE	COUNTRY/ SER. NO.	FILING DATE*	PATENT NUMBER	STATUS
SUSTAINED DELIVERY OF COMPOSTATIN ANALOGS FROM GELS	PROV	60976,919	10/02/07		Expired
"	PROV	61/026,458	02/05/08		
"	PROV	61/026,460	02/05/08		
SUSTAINED DELIVERY OF COMPOSTATIN ANALOGS FROM GELS	PCT	PCT/US2008/078593 (Published as WO/2009/046198)	10/2/08		Nationalized
"	PARENT	Egypt	10/2/08	PCT/NA/527/2010	Pending
"	PARENT	Russian Federation	10/2/08	2010113513	Issued

*	PARENT	South Africa	10/2/08	2010/02365	Issued
*	PARENT	South Korea	10/2/08	10-2010-7008703	Abandoned
*	DIV	South Korea	10/2/08	10-2015-7016589	Pending

FAMILY: ENHANCING PHAGOCYTOSIS

TITLE	APPN TYPE	COUNTRY/ SER. NO.	FILING DATE	PATENT NUMBER	STATUS
INHIBITING ANGIOGENESIS	PROV	US 60/497,986	8/22/03		Expired
CELL CLEARANCE BY SEMI-APOPTIC TAGGING	PROV	US 60/514,941	10/28/03		Expired
*	PROV	US 60/523,611	11/19/03		Expired
*	PROV	US 60/524,730	11/24/03		Expired
*	PROV	US 60/547,951	2/26/04		Expired
COMPOSITIONS AND METHODS FOR ENHANCING PHAGOCYTOSIS OR PHAGOCYTE ACTIVITY	PARENT	US 10/923,940	8/23/04	8,198,020	Issued

FAMILY: VIRAL COMPLEMENT CONTROL PROTEINS FOR EYE DISORDERS

TITLE	APPN TYPE	COUNTRY/ SER. NO.	FILING DATE	PATENT NUMBER	STATUS
TREATMENT OF MACULAR DEGENERATION AND RELATED CONDITIONS WITH POXVIRUS COMPLEMENT CONTROL PROTEINS	PROV	US 60/616,983	10/08/04		Expired
VIRAL COMPLEMENT CONTROL PROTEINS FOR EYE DISORDERS CHARACTERIZED BY INFLAMMATION	PROV	US 60/751,771	12/19/05		Expired
VIRAL COMPLEMENT CONTROL PROTEINS FOR EYE DISORDERS	PARENT	US 11/247,886	10/08/05	7,947,267	Expired
VIRAL COMPLEMENT CONTROL PROTEINS FOR EYE DISORDERS	CFP	US 11/612,751	12/19/06	8,045,609	Issued

* For national stage applications, filing date listed is filing date of corresponding PCT application